Mitch A. Phelps, PhD

Professor

Kimberly Professor of Pharmacy

Pharmaceutics and Pharmacology

Outcomes and Translational Sciences

Research Areas: Cancer, The Division of Pharmaceutics & Pharmacology, Clinical & Pre-Clinical Pharmacology

506 Riffe Building

phelps.32@osu.edu

(614) 688-4370

Professional Website

Professional Interests

Dr. Phelps’ lab is involved in both pre-clinical and clinical development of numerous small molecule anti-cancer and immuno-modulatory agents under development. Their work aims to understand the mechanisms involved in the absorption, distribution, metabolism, and excretion (i.e. pharmacokinetics, PK) of these agents, and how both the PK and pharmacodynamic (PD) effects of these agents are altered by genetic differences (polymorphisms) among individuals (i.e. pharmacogenetics, PG).

Education

2005, PhD, The Ohio State University, Biophysics
1999, MLHR, The Ohio State University, Labor and Human Resources
1992, BA, Ohio Wesleyan University, Physics

Honors

Outstanding Graduate Student Award, 2005
Predoctoral Fellowship, 2004
Predoctoral Fellowship, 2003 - 2004
Ray Travel Award, 2003
Hazel Brown Teaching Award, 2001

Publications

Data from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Jul | preprint. doi: 10.1158/2767-9764.c.7926287.
Figure 1 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Jul | preprint. doi: 10.1158/2767-9764.29557244.
Figure 2 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Jul | preprint. doi: 10.1158/2767-9764.29557241.
Figure 3 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Jul | preprint. doi: 10.1158/2767-9764.29557238.
Supplementary Figure S1 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Jul | preprint. doi: 10.1158/2767-9764.29557235.
Supplementary Figure S2 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Jul | preprint. doi: 10.1158/2767-9764.29557232.
Supplementary Figure S3 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Jul | preprint. doi: 10.1158/2767-9764.29557229.
Supplementary Figure S4 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Jul | preprint. doi: 10.1158/2767-9764.29557226.
Supplementary Methods from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Jul | preprint. doi: 10.1158/2767-9764.29557220.
Supplementary Table S1 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Jul | preprint. doi: 10.1158/2767-9764.29557217.
Supplementary Table S2 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Jul | preprint. doi: 10.1158/2767-9764.29557214.
Supplementary Table S3 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Jul | preprint. doi: 10.1158/2767-9764.29557211.
Supplementary Table S4 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Jul | preprint. doi: 10.1158/2767-9764.29557208.
Supplementary Table S5 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Jul | preprint. doi: 10.1158/2767-9764.29557205.
Supplementary Table S6 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Jul | preprint. doi: 10.1158/2767-9764.29557202.
Supplementary Table S7 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Jul | preprint. doi: 10.1158/2767-9764.29557193.
Table 1 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Jul | preprint. doi: 10.1158/2767-9764.29557190.
Table 2 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Jul | preprint. doi: 10.1158/2767-9764.29557187.
Table 3 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Jul | preprint. doi: 10.1158/2767-9764.29557184.
A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, Cancer Research Communications. 2025 Jul | journal-article. doi: 10.1158/2767-9764.CRC-25-0091.
Translational Pharmacokinetic-Pharmacodynamic Modeling of a Novel Oral Dihydroorotate Dehydrogenase (DHODH) Inhibitor, HOSU-53 (JBZ-001), Pharmaceutics. 2025 Mar | journal-article. doi: 10.3390/pharmaceutics17040412.
Antibody Drug Clearance: An Underexplored Marker of Outcomes with Checkpoint Inhibitors, Clinical Cancer Research. 2024 Mar | journal-article. doi: 10.1158/1078-0432.CCR-23-1683.
Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399, The Oncologist. 2023 Nov | journal-article. doi: 10.1093/oncolo/oyad221.
Clinical Pharmacokinetics and Pharmacodynamics of Daratumumab, Clinical Pharmacokinetics. 2023 Jun | journal-article. doi: 10.1007/s40262-023-01240-8.
Data from Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia, . 2023 Mar | preprint. doi: 10.1158/1078-0432.c.6529547.v1.
Data from Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia, . 2023 Mar | preprint. doi: 10.1158/1078-0432.c.6529547.
Supplementary Data from Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia, . 2023 Mar | preprint. doi: 10.1158/1078-0432.22476989.v1.
Supplementary Data from Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia, . 2023 Mar | preprint. doi: 10.1158/1078-0432.22476989.
Dichotomous Nitric Oxide–Dependent Post-Translational Modifications of STAT1 Are Associated with Ipilimumab Benefits in Melanoma, Cancers. 2023 Mar | journal-article. doi: 10.3390/cancers15061755.
The Neonatal Fc Receptor Is Elevated in Monocyte-Derived Immune Cells in Pancreatic Cancer, International Journal of Molecular Sciences. 2022 Jun | journal-article. doi: 10.3390/ijms23137066.
A Single Nucleotide Polymorphism (SNP) in the SLC22A3 Transporter Gene Is Associated with the Severity of Oral Mucositis in Multiple Myeloma Patients Receiving Autologous Stem Cell Transplant Followed by Melphalan Therapy, Anticancer Research. 2022 Jan | journal-article. doi: 10.21873/anticanres.15497.
Discovery of Anticancer Agents of Diverse Natural Origin, Journal of Natural Products. 2022 Jan | journal-article. doi: 10.1021/acs.jnatprod.2c00036.
PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia, Blood. 2022 Jan | journal-article. doi: 10.1182/blood.2020010344.
Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy, Clinical Lung Cancer. 2022 Jan | journal-article. doi: 10.1016/j.cllc.2021.12.010.
A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies, Cancer Chemotherapy and Pharmacology. 2021 May | journal-article. doi: 10.1007/s00280-020-04229-3.
Inhibition of androgen/AR signaling inhibits diethylnitrosamine (DEN) induced tumour initiation and remodels liver immune cell networks., Scientific reports. 2021 Feb | journal-article. doi: 10.1038/s41598-021-82252-x.
Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans., JCSM rapid communications. 2021 Feb | journal-article. doi: 10.1002/rco2.32.
Approaches to handling missing or “problematic” pharmacology data: Pharmacokinetics, CPT: Pharmacometrics and Systems Pharmacology. 2021 Jan | journal-article. doi: 10.1002/psp4.12611.
Pharmacological Prevention of Neonatal Opioid Withdrawal in a Pregnant Guinea Pig Model, Frontiers in Pharmacology. 2021 Jan | journal-article. doi: 10.3389/fphar.2020.613328.
Phase 2 study of ibrutinib in classic and variant hairy cell leukemia, Blood. 2021 Jan | journal-article. doi: 10.1182/blood.2020009688.
Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer, Gynecologic Oncology. 2021 Jan | journal-article. doi: 10.1016/j.ygyno.2021.06.032.
Population Pharmacokinetic Analysis from First-in-Human Data for HDAC Inhibitor, REC-2282 (AR-42), in Patients with Solid Tumors and Hematologic Malignancies: A Case Study for Evaluating Flat vs. Body Size Normalized Dosing, European Journal of Drug Metabolism and Pharmacokinetics. 2021 Jan | journal-article. doi: 10.1007/s13318-021-00722-z.
Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia, Clinical Cancer Research. 2020 Dec | journal-article. doi: 10.1158/1078-0432.CCR-20-1280.
A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome, American Journal of Hematology. 2020 Dec | journal-article. doi: 10.1002/ajh.25958.
A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer, Investigational New Drugs. 2020 Jan | journal-article. doi: 10.1007/s10637-020-00895-5.
Association of anril polymorphism with overall survival in adult patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation, Anticancer Research. 2020 Jan | journal-article. doi: 10.21873/anticanres.14585.
Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor, EMBO Molecular Medicine. 2020 Jan | journal-article. doi: 10.15252/emmm.201809910.
Pharmacokinetics and Tolerability of the Novel Non-immunosuppressive Fingolimod Derivative, OSU-2S, in Dogs and Comparisons with Data in Mice and Rats, AAPS Journal. 2020 Jan | journal-article. doi: 10.1208/s12248-020-00474-9.
Pharmacological prevention of neonatal opioid withdrawal in a pregnant guinea pig model., bioRxiv. 2020 Jan | other. doi: 10.1101/2020.07.25.221192.
Phase I study of AR-42 and decitabine in acute myeloid leukemia, Leukemia and Lymphoma. 2020 Jan | journal-article. doi: 10.1080/10428194.2020.1719095.
Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML, Investigational New Drugs. 2020 Jan | journal-article. doi: 10.1007/s10637-019-00786-4.
Replication study: Coding-independent regulation of the tumor suppressor pten by competing endogenous mRNAs, eLife. 2020 Jan | journal-article. doi: 10.7554/eLife.56651.
The Role of Malnutrition and Muscle Wasting in Advanced Lung Cancer, Current Oncology Reports. 2020 Jan | journal-article. doi: 10.1007/s11912-020-00916-9.
Optimising time samples for determining area under the curve of pharmacokinetic data using non-compartmental analysis, Journal of Pharmacy and Pharmacology. 2019 Nov | journal-article. doi: 10.1111/jphp.13154.
Population pharmacokinetics of lenalidomide in patients with B‐cell malignancies, British Journal of Clinical Pharmacology. 2019 May | journal-article. doi: 10.1111/bcp.13873.
A single nucleotide polymorphism in SLC7A5 was associated with clinical response in multiple myeloma patients, Anticancer Research. 2019 Jan | journal-article. doi: 10.21873/anticanres.13080.
Development of a physiologically based pharmacokinetic model for intravenous lenalidomide in mice, Cancer Chemotherapy and Pharmacology. 2019 Jan | journal-article. doi: 10.1007/s00280-019-03941-z.
Letter to the Editor: Exposure–response or clearance–response relationship in immune checkpoint therapy?—A comment on ‘correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer’ by Basak et al, European Journal of Cancer. 2019 Jan | journal-article. doi: 10.1016/j.ejca.2019.02.017.
ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model, Blood. 2019 Jan | journal-article. doi: 10.1182/blood.2018882290.
SuV39H1 represses the expression of cytotoxic T-lymphocyte effector genes to promote colon tumor immune evasion, Cancer Immunology Research. 2019 Jan | journal-article. doi: 10.1158/2326-6066.CIR-18-0126.
The Extracellular RNA Communication Consortium: Establishing Foundational Knowledge and Technologies for Extracellular RNA Research, Cell. 2019 Jan | journal-article. doi: 10.1016/j.cell.2019.03.023.
XRCC1-mediated DNA repair is associated with progression-free survival of multiple myeloma patients after autologous stem cell transplant, Molecular Carcinogenesis. 2019 Jan | journal-article. doi: 10.1002/mc.23121.
Cachectic Cancer Patients: Immune to Checkpoint Inhibitor Therapy?, Clinical Cancer Research. 2018 Dec | journal-article. doi: 10.1158/1078-0432.CCR-18-1847.
CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128, Oncotarget. 2018 Jan | journal-article. doi: 10.18632/oncotarget.25430.
Erratum: Author Correction: Nitric oxide mediated inhibition of antigen presentation from DCs to CD4⁺ T cells in cancer and measurement of STAT1 nitration (Scientific reports (2017) 7 1 (15424)), Scientific reports. 2018 Jan | journal-article. doi: 10.1038/s41598-018-21306-z.
PRMT5 as a druggable target for glioblastoma therapy, Neuro-Oncology. 2018 Jan | journal-article. doi: 10.1093/neuonc/nox206.
Pharmacokinetic-Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving High-Dose Melphalan for Autologous Stem Cell Transplant, CPT: Pharmacometrics and Systems Pharmacology. 2018 Jan | journal-article. doi: 10.1002/psp4.12345.
Phase I trial of dabrafenib and pazopanib in BRAF mutated advanced malignancies, JCO Precision Oncology. 2018 Jan | journal-article. doi: 10.1200/PO.17.00247.
Phyllanthusmin derivatives induce apoptosis and reduce tumor burden in high-grade serous ovarian cancer by late-stage autophagy inhibition, Molecular Cancer Therapeutics. 2018 Jan | journal-article. doi: 10.1158/1535-7163.MCT-17-1195.
Rituximab immunotherapy: it’s getting personal, Blood. 2017 May | journal-article. doi: 10.1182/blood-2017-03-772061.
A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma, Clinical Lymphoma, Myeloma and Leukemia. 2017 Jan | journal-article. doi: 10.1016/j.clml.2017.05.008.
A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas, Leukemia and Lymphoma. 2017 Jan | journal-article. doi: 10.1080/10428194.2017.1298751.
Achieving the Promise of Therapeutic Extracellular Vesicles: The Devil is in Details of Therapeutic Loading, Pharmaceutical Research. 2017 Jan | journal-article. doi: 10.1007/s11095-017-2123-5.
Associations of High-Dose Melphalan Pharmacokinetics and Outcomes in the Setting of a Randomized Cryotherapy Trial, Clinical Pharmacology and Therapeutics. 2017 Jan | journal-article. doi: 10.1002/cpt.644.
Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells, Journal of Extracellular Vesicles. 2017 Jan | journal-article. doi: 10.1080/20013078.2017.1324730.
G-CSF improves safety when you start the day after autologous transplant in multiple myeloma, Leukemia and Lymphoma. 2017 Jan | journal-article. doi: 10.1080/10428194.2017.1318436.
Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-Glucuronide, Clinical and Translational Science. 2017 Jan | journal-article. doi: 10.1111/cts.12458.
Low active loading of cargo into engineered extracellular vesicles results in inefficient miRNA mimic delivery, Journal of Extracellular Vesicles. 2017 Jan | journal-article. doi: 10.1080/20013078.2017.1333882.
Nitric oxide mediated inhibition of antigen presentation from DCs to CD4⁺ T cells in cancer and measurement of STAT1 nitration, Scientific Reports. 2017 Jan | journal-article. doi: 10.1038/s41598-017-14970-0.
Non-immunosuppressive FTY720-derivative OSU-2S mediates reactive oxygen species-mediated cytotoxicity in canine B-cell lymphoma, Veterinary and Comparative Oncology. 2017 Jan | journal-article. doi: 10.1111/vco.12221.
Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study, PLoS Medicine. 2017 Jan | journal-article. doi: 10.1371/journal.pmed.1002382.
Overcoming Resistance to Anabolic Selective Androgen Receptor Modulator (SARM) Therapy in Experimental Cancer Cachexia with Histone Deacetylase Inhibitor AR-42, bioRxiv. 2017 Jan | other. doi: 10.1101/214155.
Plasma pharmacokinetics and bioavailability of verticillin A following different routes of administration in mice using liquid chromatography tandem mass spectrometry, Journal of Pharmaceutical and Biomedical Analysis. 2017 Jan | journal-article. doi: 10.1016/j.jpba.2017.02.051.
Polymorphism in ANRIL is associated with relapse in patients with multiple myeloma after autologous stem cell transplant, Molecular Carcinogenesis. 2017 Jan | journal-article. doi: 10.1002/mc.22626.
Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing’s sarcoma, and rhabdomyosarcoma, PLoS ONE. 2017 Jan | journal-article. doi: 10.1371/journal.pone.0181885.
A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma, Leukemia and Lymphoma. 2016 Jan | journal-article. doi: 10.3109/10428194.2015.1129536.
Discovery and Mechanism of Highly Efficient Cyclic Cell-Penetrating Peptides, Biochemistry. 2016 Jan | journal-article. doi: 10.1021/acs.biochem.6b00226.
Discovery of anticancer agents of diverse natural origin, Anticancer Research. 2016 Jan | journal-article. doi: 10.21873/anticanres.11146.
In vitro immunotoxicity assessment of culture-derived extracellular vesicles in human monocytes, Journal of Immunotoxicology. 2016 Jan | journal-article. doi: 10.3109/1547691X.2016.1148089.
NK Cell-Mediated antitumor effects of a folate-conjugated immunoglobulin are enhanced by cytokines, Cancer Immunology Research. 2016 Jan | journal-article. doi: 10.1158/2326-6066.CIR-15-0168.
Pharmacokinetics of intra-articular betamethasone sodium phosphate and betamethasone acetate and endogenous hydrocortisone suppression in exercising horses, Journal of Veterinary Pharmacology and Therapeutics. 2016 Jan | journal-article. doi: 10.1111/jvp.12229.
Preclinical pharmacokinetics study of R- and S-Enantiomers of the histone deacetylase inhibitor, AR-42 (NSC 731438), in rodents, AAPS Journal. 2016 Jan | journal-article. doi: 10.1208/s12248-016-9876-3.
Preferential delivery of an opioid antagonist to the fetal brain in pregnant mice, Journal of Pharmacology and Experimental Therapeutics. 2016 Jan | journal-article. doi: 10.1124/jpet.115.231902.
Preparation and Evaluation of a Novel Class of Amphiphilic Amines as Antitumor Agents and Nanocarriers for Bioactive Molecules, Pharmaceutical Research. 2016 Jan | journal-article. doi: 10.1007/s11095-016-1999-9.
Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers, Journal of Proteomics. 2016 Jan | journal-article. doi: 10.1016/j.jprot.2015.12.016.
Registered report: Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs, eLife. 2016 Jan | journal-article. doi: 10.7554/eLife.12470.
Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia, Blood. 2015 Jan | journal-article. doi: 10.1182/blood-2014-10-607648.
Liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of simvastatin, lovastatin, atorvastatin, and their major metabolites in human plasma, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2015 Jan | journal-article. doi: 10.1016/j.jchromb.2014.12.029.
OSU-T315: A novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells, Blood. 2015 Jan | journal-article. doi: 10.1182/blood-2014-06-583518.
Phase i dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma, Leukemia and Lymphoma. 2015 Jan | journal-article. doi: 10.3109/10428194.2015.1014368.
ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo, Experimental Hematology. 2015 Jan | journal-article. doi: 10.1016/j.exphem.2015.04.008.
Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL), American Journal of Hematology. 2015 Jan | journal-article. doi: 10.1002/ajh.23946.
Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer, Scientific Reports. 2015 Jan | journal-article. doi: 10.1038/srep12122.
The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma, British Journal of Haematology. 2015 Jan | journal-article. doi: 10.1111/bjh.13354.
Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia, Leukemia. 2015 Jan | journal-article. doi: 10.1038/leu.2014.199.
A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia, Leukemia Research. 2014 Jan | journal-article. doi: 10.1016/j.leukres.2014.05.011.
A novel liposomal formulation of FTY720 (Fingolimod) for promising enhanced targeted delivery, Nanomedicine: Nanotechnology, Biology, and Medicine. 2014 Jan | journal-article. doi: 10.1016/j.nano.2013.08.001.
A phase I trial of flavopiridol in relapsed multiple myeloma, Cancer Chemotherapy and Pharmacology. 2014 Jan | journal-article. doi: 10.1007/s00280-013-2347-y.
A snapshot of challenges and solutions in cancer drug development and therapy, Clinical Pharmacology and Therapeutics. 2014 Jan | journal-article. doi: 10.1038/clpt.2014.15.
Comparison of high-dose intermittent and low-dose continuous oral artemisinin in dogs with naturally occurring tumors, Journal of the American Animal Hospital Association. 2014 Jan | journal-article. doi: 10.5326/JAAHA-MS-6145.
Erlotinib in African Americans with advanced non-small cell lung cancer: A prospective randomized study with genetic and pharmacokinetic analyses, Clinical Pharmacology and Therapeutics. 2014 Jan | journal-article. doi: 10.1038/clpt.2014.93.
Establishing a clinical pharmacology fellowship program for physicians, pharmacists, and pharmacologists: A newly accredited interdisciplinary training program at the Ohio State University, Advances in Medical Education and Practice. 2014 Jan | journal-article. doi: 10.2147/AMEP.S60986.
Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma, American Journal of Hematology. 2014 Jan | journal-article. doi: 10.1002/ajh.23568.
Irinotecan pharmacogenetics: A finished puzzle?, Journal of Clinical Oncology. 2014 Jan | journal-article. doi: 10.1200/JCO.2014.56.3387.
Quantification of OSU-2S, a novel derivative of FTY720, in mouse plasma by liquid chromatography-tandem mass spectrometry, Journal of Pharmaceutical and Biomedical Analysis. 2014 Jan | journal-article. doi: 10.1016/j.jpba.2014.05.022.
Race and ethnicity in cancer therapy: What have we learned?, Clinical Pharmacology and Therapeutics. 2014 Jan | journal-article. doi: 10.1038/clpt.2014.5.
Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue, Journal of Pharmaceutical and Biomedical Analysis. 2014 Jan | journal-article. doi: 10.1016/j.jpba.2013.08.036.
A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol, Clinical Cancer Research. 2013 Jan | journal-article. doi: 10.1158/1078-0432.CCR-12-1092.
A phase i study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors, Investigational New Drugs. 2013 Jan | journal-article. doi: 10.1007/s10637-012-9863-1.
CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid control, Drug Metabolism and Drug Interactions. 2013 Jan | journal-article. doi: 10.1515/dmdi-2012-0031.
Comparative cellular pharmacokinetics and pharmacodynamics of siRNA delivery by SPANosomes and by cationic liposomes, Nanomedicine: Nanotechnology, Biology, and Medicine. 2013 Jan | journal-article. doi: 10.1016/j.nano.2012.10.002.
Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia, Leukemia Research. 2013 Jan | journal-article. doi: 10.1016/j.leukres.2013.06.006.
Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74⁺ B-cell malignancies, Clinical Cancer Research. 2013 Jan | journal-article. doi: 10.1158/1078-0432.CCR-12-2046.
Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia, Leukemia and Lymphoma. 2013 Jan | journal-article. doi: 10.3109/10428194.2012.760733.
Site specific discrete PEGylation of ¹²⁴I-labeled mCC49 Fab′ fragments improves tumor MicroPET/CT imaging in mice, Bioconjugate Chemistry. 2013 Jan | journal-article. doi: 10.1021/bc400375f.
Standard pentostatin dose reductions in renal insufficiency are not adequate: Selected patients with steroid-refractory acute graft-versus-host disease, Clinical Pharmacokinetics. 2013 Jan | journal-article. doi: 10.1007/s40262-013-0064-7.
Toxicology and biodistribution studies for MGH2.1, an oncolytic virus that expresses two prodrug-activating genes, in combination with prodrugs, Molecular Therapy - Nucleic Acids. 2013 Jan | journal-article. doi: 10.1038/mtna.2013.38.
A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors, Investigational New Drugs. 2012 Jan | journal-article. doi: 10.1007/s10637-010-9563-7.
Acetaminophen pediatric dose selection: Caregiver satisfaction regarding the antipyretic efficacy of acetaminophen in children, Clinical Pediatrics. 2012 Jan | journal-article. doi: 10.1177/0009922812456592.
Analysis of the transport of and cytotoxic effects for nalbuphine solution in corneal cells, American Journal of Veterinary Research. 2012 Jan | journal-article. doi: 10.2460/ajvr.73.12.1987.
Development and validation of sensitive liquid chromatography/tandem mass spectrometry method for quantification of bendamustine in mouse brain tissue, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2012 Jan | journal-article. doi: 10.1016/j.jchromb.2012.08.013.
Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach, Haematologica. 2012 Jan | journal-article. doi: 10.3324/haematol.2011.047324.
Influence of exercise on the distribution of technetium Tc 99m medronate following intra-articular injection in horses, American Journal of Veterinary Research. 2012 Jan | journal-article. doi: 10.2460/ajvr.73.3.418.
Institutional profile: Program in pharmacogenomics at the ohio state university medical Center, Pharmacogenomics. 2012 Jan | journal-article. doi: 10.2217/pgs.12.46.
Pharmacokinetics and tissue disposition of lenalidomide in mice, AAPS Journal. 2012 Jan | journal-article. doi: 10.1208/s12248-012-9401-2.
Pharmacokinetics of methylprednisolone acetate after intra-articular administration and subsequent suppression of endogenous hydrocortisone secretion in exercising horses, American Journal of Veterinary Research. 2012 Jan | journal-article. doi: 10.2460/ajvr.73.9.1453.
Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples, Modern Pathology. 2012 Jan | journal-article. doi: 10.1038/modpathol.2012.95.
Reply to N. Chen et al, Journal of Clinical Oncology. 2012 Jan | journal-article. doi: 10.1200/JCO.2011.39.6101.
Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines, PLoS ONE. 2012 Jan | journal-article. doi: 10.1371/journal.pone.0040724.
6β-Naltrexol, a Peripherally Selective Opioid Antagonist that Inhibits Morphine-Induced Slowing of Gastrointestinal Transit: An Exploratory Study, Pain Medicine. 2011 Jan | journal-article. doi: 10.1111/j.1526-4637.2011.01279.x.
Characterization of silvestrol pharmacokinetics in mice using liquid chromatography-tandem mass spectrometry, AAPS Journal. 2011 Jan | journal-article. doi: 10.1208/s12248-011-9273-x.
Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers, Journal of Clinical Oncology. 2011 Jan | journal-article. doi: 10.1200/JCO.2010.33.9473.
Pharmacogenomic testing: Relevance in medical practice: Why drugs work in some patients but not in others, Cleveland Clinic Journal of Medicine. 2011 Jan | journal-article. doi: 10.3949/ccjm.78a.10145.
Pharmacokinetics of oral ivabradine in healthy cats, Journal of Veterinary Pharmacology and Therapeutics. 2011 Jan | journal-article. doi: 10.1111/j.1365-2885.2010.01253.x.
Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: Evidence for lenalidomide-CCI-779 interaction via P-glycoprotein, Journal of Clinical Oncology. 2011 Jan | journal-article. doi: 10.1200/JCO.2010.32.4962.
Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cells, AAPS Journal. 2011 Jan | journal-article. doi: 10.1208/s12248-011-9276-7.
Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol, Leukemia. 2011 Jan | journal-article. doi: 10.1038/leu.2011.109.
miR-221 silencing blocks hepatocellular carcinoma and promotes survival, Cancer Research. 2011 Jan | journal-article. doi: 10.1158/0008-5472.CAN-11-1144.
Dose escalation of lenalidomide in relapsed or refractory acute leukemias, Journal of Clinical Oncology. 2010 Jan | journal-article. doi: 10.1200/JCO.2010.30.3339.
Flavopiridol Pharmacogenetics: Clinical and Functional Evidence for the Role of SLCO1B1/OATP1B1 in Flavopiridol Disposition, PLoS ONE. 2010 Jan | journal-article. doi: 10.1371/journal.pone.0013792.
Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias, Haematologica. 2010 Jan | journal-article. doi: 10.3324/haematol.2009.017103.
REO-10: A phase I study of intravenous reovirus and docetaxel in patients with advanced cancer, Clinical Cancer Research. 2010 Jan | journal-article. doi: 10.1158/1078-0432.CCR-10-1233.
A novel liposomal formulation of flavopiridol, International Journal of Pharmaceutics. 2009 Jan | journal-article. doi: 10.1016/j.ijpharm.2008.08.008.
A phase I/II dose escalation study of Apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia, Leukemia and Lymphoma. 2009 Jan | journal-article. doi: 10.3109/10428190903186486.
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia, Blood. 2009 Jan | journal-article. doi: 10.1182/blood-2008-07-168583.
Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease, Journal of Clinical Oncology. 2009 Jan | journal-article. doi: 10.1200/JCO.2009.22.6944.
Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma, Therapeutic Drug Monitoring. 2008 Jan | journal-article. doi: 10.1097/FTD.0b013e318185813d.
Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2008 Jan | journal-article. doi: 10.1016/j.jchromb.2008.06.029.
Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2008 Jan | journal-article. doi: 10.1016/j.jchromb.2008.04.023.
Flavopiridol (alvocidib) in chronic lymphocytic leukemia, Haematologica Meeting Reports. 2008 Jan | journal-article. .
Inhibitors of tubulin assembly identified through screening a compound library, Chemical Biology and Drug Design. 2008 Jan | journal-article. doi: 10.1111/j.1747-0285.2008.00729.x.
Intracellular processing of riboflavin in human breast cancer cells, Molecular Pharmaceutics. 2008 Jan | journal-article. doi: 10.1021/mp800046m.
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia, Blood. 2007 Jan | journal-article. doi: 10.1182/blood-2006-05-020735.
Antikinetoplastid antimitotic activity and metabolic stability of dinitroaniline sulfonamides and benzamides, Bioorganic and Medicinal Chemistry. 2006 Jan | journal-article. doi: 10.1016/j.bmc.2006.04.017.
Recognition, cointernalization, and recycling of an avian riboflavin carrier protein in human placental trophoblasts, Journal of Pharmacology and Experimental Therapeutics. 2006 Jan | journal-article. doi: 10.1124/jpet.105.096149.
Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats, Endocrinology. 2005 Jan | journal-article. doi: 10.1210/en.2005-0572.
A novel rhodamine-riboflavin conjugate probe exhibits distinct fluorescence resonance energy transfer that enables riboflavin trafficking and subcellular localization studies., Molecular pharmaceutics. 2004 Jan | journal-article. doi: 10.1021/mp0499510.
Favorable Effects of Weak Acids on Negative-Ion Electrospray Ionization Mass Spectrometry, Analytical Chemistry. 2004 Jan | journal-article. doi: 10.1021/ac0351670.
Topology scanning and putative three-dimensional structure of the extracellular binding domains of the apical sodium-dependent bile acid transporter (SLC10A2), Biochemistry. 2004 Jan | journal-article. doi: 10.1021/bi049270a.
Cytoskeletal motors and cargo in membrane trafficking: Opportunities for high specificity in drug intervention, Drug Discovery Today. 2003 Jan | journal-article. doi: 10.1016/S1359-6446(03)02707-7.
Involvement of endocytic organelles in the subcellular trafficking and localization of riboflavin, Journal of Pharmacology and Experimental Therapeutics. 2003 Jan | journal-article. doi: 10.1124/jpet.103.051581.
Modeling of active transport systems, Advanced Drug Delivery Reviews. 2002 Jan | journal-article. doi: 10.1016/S0169-409X(02)00007-8.